OR-316

N/A

Report date: 2025/06/11 11:17:24

Base Information

Drug NameOR-316

Drug Alias Nameanti-siglec-15 mAb (OncoResponse)siglec-15 checkpoint inhibitor (OncoResponse)anti-sialic acid binding Ig-like lectin 15 antibody (OncoResponse)OR-3479OR-316

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionSialic acid-binding Ig-like lectin 15 inhibitorsImmunostimulantsMacrophages stimulants

TargetsSialic acid-binding Ig-like lectin 15

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOncoResponse Inc

China Registration ClassN/A

Develop Information

Active CompaniesOncoResponse Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A